Sichuan Biokin Pharmaceutical Co. Ltd. A (688506.SS) stock: key figures, P/E, revenue and dividend
Health Care · China · ISIN CNE100006FN4
Sichuan Biokin Pharmaceutical Co. Ltd. A financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 5.82 bn CNY | 2.52 bn CNY |
| Gross profit | 5.56 bn CNY | 2.29 bn CNY |
| Operating income | 3.74 bn CNY | -743.36 m CNY |
| EBIT | 4.02 bn CNY | -636.36 m CNY |
| Net income | 3.71 bn CNY | -1.05 bn CNY |
| Diluted EPS – continuing operations | 9.25 CNY | -2.55 CNY |
Full history since 2021, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Sichuan Biokin Pharmaceutical Co. Ltd. A
Sichuan Biokin Pharmaceutical Co.,Ltd. engages in the research and development, manufacture, and sale of biomedicine in the fields of antibody drug conjugate, guidance navigation and control, and antibody radionuclide conjugate in China and internationally. It offers anesthesia, parenteral nutrition, anti-infectives, pediatrics, and traditional Chinese medicines. The company was founded in 1996 and is headquartered in Chengdu, China.
More stocks
- Symrise (SY1.DE)
- National Bank of Greece SA (ETE.AT)
- TransUnion (TRU)
- Admiral Group PLC (ADM.L)
- China International Travel Service Corp Ltd (601888.SS)
- Metso Oyj (METSO.HE)
- mBank SA (MBK.WA)
- Corebridge Financial, Inc. (CRBG)
- Kanzhun Ltd (BZ)
- Huazhu Group Ltd (HTHT)
- KGHM Polska Miedz SA (KGH.WA)
- Insurance Australia Group Ltd (IAG.AX)
Not investment advice. All data without warranty, price as of 23.10.2026. Details in the risk notice.